

July 2, 2018

**Open Call for Applicants for
investigator-Initiated Clinical Research Funds
- We Ensure Transparency and Support Investigator-Initiated
Research Based on Japan's Clinical Research Act -**

Mitsubishi Tanabe Pharma Corporation (hereafter "MTPC"; Head Office: Chuo-ku, Osaka; President & Representative Director: Masayuki Mitsuka) announced today that MTPC has launched a website as of July 2, 2018, to publicly call for applicants for Investigator-Initiated Study (IIS) funds.

[Overview of the Open Call]

◆Objective :

To provide study funds in order to support IIS which use MTPC's pharmaceuticals.

◆Eligible study:

Study using the pharmaceuticals manufactured and marketed by MTPC within the range of approval based on the Pharmaceutical and Medical Device Act

◆Eligible Candidates (Applicants) :

Principal investigator of the above-mentioned study (medical doctors or dentists residing in Japan)

◆Eligible Fields/Pharmaceuticals/Research Themes:

Study related to the following disease fields, pharmaceuticals, and/or research themes* (see the next page for details)

Diabetes (Canaglu, Tenelia, Canalia)

Allergic Diseases (Rupafin)

◆Application Period:

From Monday, July 2, 2018, to Sunday, March 31, 2019 (for FY 2018)

◆How to Apply:

Applications shall be made via the "Open-Call Program for Investigator-Initiated Study" on our website.

For details, please check the page for the "Open-Call Program for Investigator-Initiated Study".

"Open-Call Program for Investigator-Initiated Study"

<https://www.mt-pharma.co.jp/shared/show.php?url=../develop/iis/index.html>

We will promote appropriate use of our pharmaceuticals by providing support for IIS.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department

Media Contacts: TEL: +81 6 6205 5119

Investor Contacts: TEL: +81 6 6205 5110

* Details of the Open Call: Eligible disease fields/pharmaceuticals/research themes are as follows.

【Diabetes】

Pharmaceutical Name: Canaglu[®] Tablets 100mg (Generic Name: Canagliflozin)

- Study on the efficacy and safety concerning variability of blood glucose levels in patients with type 2 diabetes mellitus
- Study on the mechanism of action of cardioprotection/renoprotection in patients with type 2 diabetes mellitus
- Study on the safety of pathological conditions associated with type 2 diabetes mellitus
- Study on eating habits and exercise therapy in patients with type 2 diabetes mellitus

Pharmaceutical Name: Tenelia[®] Tablets 20mg (Generic Name: Tenzeligliptin)

- Study on the efficacy and safety concerning variability of blood glucose levels in elderly patients with type 2 diabetes mellitus
- Study on the efficacy and safety of type 2 diabetes mellitus complicated by renal dysfunction

Pharmaceutical Name: Canalia[®] Combination Tablets (Generic Name: Tenzeligliptin / Canagliflozin)

- Study on the efficacy and safety concerning variability of blood glucose levels in patients with type 2 diabetes mellitus
- Study on improvement of adherence in patients with type 2 diabetes mellitus

【Allergic Diseases】

Pharmaceutical Name: Rupafin[®] Tablets 10mg (Generic Name: Rupatadine)

- Study on the efficacy and safety concerning allergic rhinitis, urticaria, and skin disease
- Study on the efficacy and safety concerning itching sensations due to atopic dermatitis